Results 41 to 50 of about 226,619 (252)

¹⁸F-fluorodeoxyglucose positron emission tomography combined with computed tomography in squamous cell carcinoma of the head and neck (literature review)

Опухоли головы и шеи, 2019
Most of the malignant neoplasms of the head and neck are represented by squamous cell carcinoma. 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in squamous cell carcinoma of the head and neck is applied for primary ...
О. D. Ryzhova, М. B. Dolgushin, A. I. Mikhaylov, Е. L. Dronova, D. I. Nevzorov, А. М. Mudunov, S. B. Alieva   +6 more
doaj   +1 more source

Extraskeletal myxoid chondrosarcoma of the masticator space in a pediatric patient [PDF]

, 2017
Extraskeletal myxoid chondrosarcoma (EMC) is a malignant soft-tissue neoplasm rarely described in the head and neck region of children and adolescents. We describe a case of EMC affecting the masticator space and a literature review.
Almeida, Oslei Paes de, Andrade, Bruno Augusto Benevenuto de, Carlos, Román, Nuyens, Michel, Romañach, Mário José   +4 more
core   +1 more source

Myxoid Neurothekeoma of the Nipple [PDF]

, 2011
Neurothekeomas are rare benign cutaneous neoplasms of nerve sheath origin. They are primarily found in the superficial soft tissue and are also known as dermal nerve sheath myxomas. They are commonly found on the upper extremities, head and neck followed
Indira, CS, Shivakumar, S, Thejaswini, MU, Vijaya Shankar, S   +3 more
core  

Advanced head and neck cancer: Long-term results of chemo-radiotherapy, complications and induction of second malignancies [PDF]

, 2001
Background: Chemo-radiotherapy is superior to radiotherapy alone in the treatment of advanced, inoperable head and neck cancer. The long-term treatment results, the induction of second malignant tumors, and other long-term toxicities are not well defined.
Aydemir, Ü., Hartenstein, R., Munker, Reinhold, Pohlmann, H., Purmale, L., Reitmeier, M., Schorer, H.   +6 more
core   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Advanced Oropharyngeal Cancer Can Be Easily Missed During Esophagogastroduodenoscopy [PDF]

The case of an elderly man with an advanced oropharyngeal cancer that was missed during esophagogastroduodenoscopy is described. He was referred for endoscopic resection of superficial esophageal squamous cell neoplasms.
Akasaka, Tomofumi, Hamada, Kenta, Ishihara, Ryu, Yamasaki, Yasushi   +3 more
core   +1 more source

How to evaluate and assess quality of life issues in head and neck cancer patients. [PDF]

, 2017
Purpose of review: Review quality of life (QOL) concepts and most common instruments to be used in patients with head and neck cancer, as well as the potential benefits and limitations of information derived from QOL studies. Recent findings: Information
Kowalski, LP, Rogers, Simon, Vartanian, JG   +2 more
core   +1 more source

Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma

Molecular Oncology, EarlyView.
The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias, Ana Oitabén, Sonia Zumalave, Bernardo Rodriguez‐Martin, María Gallardo‐Gómez, Martín Santamarina, Ana Pequeño‐Valtierra, Laura Juaneda‐Magdalena, Ramón García‐Escudero, José Luis López‐Cedrún, Máximo Fraga, José M. C. Tubio, Mónica Martínez‐Fernández   +12 more
wiley   +1 more source

Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer—the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis [PDF]

, 2014
Increased glucose uptake mediated by glucose transporters and reliance on glycolysis are common features of malignant cells. Hypoxia-inducible factor-1α supports the adaptation of hypoxic cells by inducing genes related to glucose metabolism.
Anna Krześlak, AP Demasi, AW Eckert, AW Eckert, BW Kim, C Zhang, CM Douglas, DE Burstein, DW Li, E Cadman, Ewa Brzezińska-Błaszczyk, Ewa Forma, FR Ayala, GL Semenza, H Kaida, H Kaida, Iwona Lewy-Trenda, J Xie, JL Roh, JL Thorne, K Müssig, K Starska, Katarzyna Starska, L Lan, L Zhang, M Kobayashi, M Mueckler, M Shimanishi, Magdalena Bryś, ML Schrijvers, O Koperek, OJ Kwon, Paweł Jóźwiak, R Cabanillas, R Ciampi, R Rashmi, S Kondo, S Ohba, S Zhou, SB Edge, SW Jing, SX Yan, T Yamada, W Fenske, W Ping, X Zhang, XH Chen, XH Wu, XP Sun, Y Cui, Y Kondo, YY Xu   +51 more
core   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source